Comparative Pharmacology
Head-to-head clinical analysis: ALSUMA versus ZOMIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALSUMA versus ZOMIG.
ALSUMA vs ZOMIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a protein required for synaptic vesicle fusion.
Selective 5-HT1B/1D receptor agonist; constricts cranial blood vessels and inhibits trigeminal nerve transmission.
0.5 mg intramuscularly every 4 weeks
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed, maximum 10 mg in 24 hours. Also available as 5 mg nasal spray and 3 mg subcutaneous injection.
None Documented
None Documented
Terminal elimination half-life: 9-11 hours; clinically, steady-state achieved in ~2 days
Mean terminal elimination half-life is approximately 3 hours (range 2.5-4 hours). In patients with hepatic impairment, half-life may be prolonged (up to 7 hours).
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Primarily hepatic metabolism via CYP1A2; approximately 10-15% excreted unchanged in urine, with the remainder eliminated as metabolites (mostly N-desmethylzolmitriptan and indoleacetic acid) in urine (60%) and feces (30%).
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine